Skip to main content
Erschienen in: Osteoporosis International 3/2018

07.12.2017 | Original Article

Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study

verfasst von: K. H. Rubin, M. J. Rothmann, T. Holmberg, M. Høiberg, S. Möller, R. Barkmann, C. C. Glüer, A. P. Hermann, M. Bech, J. Gram, K. Brixen

Erschienen in: Osteoporosis International | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Summary

The Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study investigated the effectiveness of a two-step screening program for osteoporosis in women. We found no overall reduction in fractures from systematic screening compared to the current case-finding strategy. The group of moderate- to high-risk women, who accepted the invitation to DXA, seemed to benefit from the program.

Introduction

The purpose of the ROSE study was to investigate the effectiveness of a two-step population-based osteoporosis screening program using the Fracture Risk Assessment Tool (FRAX) derived from a self-administered questionnaire to select women for DXA scan. After the scanning, standard osteoporosis management according to Danish national guidelines was followed.

Methods

Participants were randomized to either screening or control group, and randomization was stratified according to age and area of residence. Inclusion took place from February 2010 to November 2011. Participants received a self-administered questionnaire, and women in the screening group with a FRAX score ≥ 15% (major osteoporotic fractures) were invited to a DXA scan. Primary outcome was incident clinical fractures. Intention-to-treat analysis and two per-protocol analyses were performed.

Results

A total of 3416 fractures were observed during a median follow-up of 5 years. No significant differences were found in the intention-to-treat analyses with 34,229 women included aged 65–80 years. The per-protocol analyses showed a risk reduction in the group that underwent DXA scanning compared to women in the control group with a FRAX ≥ 15%, in regard to major osteoporotic fractures, hip fractures, and all fractures. The risk reduction was most pronounced for hip fractures (adjusted SHR 0.741, p = 0.007).

Conclusions

Compared to an office-based case-finding strategy, the two-step systematic screening strategy had no overall effect on fracture incidence. The two-step strategy seemed, however, to be beneficial in the group of women who were identified by FRAX as moderate- or high-risk patients and complied with DXA.
Literatur
2.
Zurück zum Zitat Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146(1):51–56CrossRefPubMed Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146(1):51–56CrossRefPubMed
8.
Zurück zum Zitat Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155 Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155
9.
Zurück zum Zitat Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282(7):637–645. https://doi.org/10.1001/jama.282.7.637 CrossRefPubMed Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282(7):637–645. https://​doi.​org/​10.​1001/​jama.​282.​7.​637 CrossRefPubMed
10.
Zurück zum Zitat Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468. https://doi.org/10.1056/NEJMoa022436 CrossRefPubMed Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468. https://​doi.​org/​10.​1056/​NEJMoa022436 CrossRefPubMed
11.
Zurück zum Zitat Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. https://doi.org/10.1056/NEJMoa067312 CrossRefPubMed Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. https://​doi.​org/​10.​1056/​NEJMoa067312 CrossRefPubMed
13.
Zurück zum Zitat Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387–396CrossRefPubMed Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387–396CrossRefPubMed
15.
Zurück zum Zitat Aboyoussef M, Vierkoetter KR (2007) Underdiagnosis and under-treatment of osteoporosis following fragility fracture. Hawaii Med J 66(7):185–187PubMed Aboyoussef M, Vierkoetter KR (2007) Underdiagnosis and under-treatment of osteoporosis following fragility fracture. Hawaii Med J 66(7):185–187PubMed
16.
Zurück zum Zitat Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84-A(8):1342–1348CrossRefPubMed Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84-A(8):1342–1348CrossRefPubMed
18.
Zurück zum Zitat US Preventive Services Task Force Guides to Clinical Preventive Services (2012) The Guide to Clinical Preventive Services 2012: Recommendations of the US Preventive Services Task Force. Agency for Healthcare Research and Quality (US), Rockville US Preventive Services Task Force Guides to Clinical Preventive Services (2012) The Guide to Clinical Preventive Services 2012: Recommendations of the US Preventive Services Task Force. Agency for Healthcare Research and Quality (US), Rockville
21.
Zurück zum Zitat Rubin KH, Abrahamsen B, Hermann AP, Bech M, Gram J, Brixen K (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39(3):312–318CrossRefPubMed Rubin KH, Abrahamsen B, Hermann AP, Bech M, Gram J, Brixen K (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39(3):312–318CrossRefPubMed
23.
Zurück zum Zitat Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Discharge Register. A valuable source of data for modern health. Science:263–268 Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Discharge Register. A valuable source of data for modern health. Science:263–268
26.
Zurück zum Zitat Dansk Knoglemedicinsk S, Danish Bonemedical S (2012) Vejledning til udredning og behandling of Osteoporose. [Instructions to diagnosis and treatment of osteoporosis] Dansk Knoglemedicinsk S, Danish Bonemedical S (2012) Vejledning til udredning og behandling of Osteoporose. [Instructions to diagnosis and treatment of osteoporosis]
28.
Zurück zum Zitat National Osteoporosis F (2013) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC National Osteoporosis F (2013) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC
30.
Zurück zum Zitat Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O’Neill T, Torgerson D, Holland R, Howe A, Marshall T, Kanis JA, McCloskey E (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 23(10):2507–2515. https://doi.org/10.1007/s00198-011-1876-7 CrossRefPubMed Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O’Neill T, Torgerson D, Holland R, Howe A, Marshall T, Kanis JA, McCloskey E (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 23(10):2507–2515. https://​doi.​org/​10.​1007/​s00198-011-1876-7 CrossRefPubMed
31.
Zurück zum Zitat McCloskey EV, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I et al (2016) Screening based on FRAX fracture risk assessment reduces the incidence of hip fractures in older community-dwelling women—results from the SCOOP study in the UK. ASBMR: J Bone Miner Res 31(Suppl 1):2016 McCloskey EV, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I et al (2016) Screening based on FRAX fracture risk assessment reduces the incidence of hip fractures in older community-dwelling women—results from the SCOOP study in the UK. ASBMR: J Bone Miner Res 31(Suppl 1):2016
32.
Zurück zum Zitat Barr RJ, Stewart A, Torgerson DJ, Seymour DG, Reid DM (2005) Screening elderly women for risk of future fractures—participation rates and impact on incidence of falls and fractures. Calcif Tissue Int 76(4):243–248CrossRefPubMed Barr RJ, Stewart A, Torgerson DJ, Seymour DG, Reid DM (2005) Screening elderly women for risk of future fractures—participation rates and impact on incidence of falls and fractures. Calcif Tissue Int 76(4):243–248CrossRefPubMed
33.
Zurück zum Zitat Lacroix AZ, Buist DS, Brenneman SK, Abbott TA III (2005) Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. Med Care 43(3):293–302CrossRefPubMed Lacroix AZ, Buist DS, Brenneman SK, Abbott TA III (2005) Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. Med Care 43(3):293–302CrossRefPubMed
35.
Zurück zum Zitat Schneider DL, Worley K, Beard MK, Iannini M, Ko M, McCallum J et al (2010) The primary care osteoporosis risk of fracture screening (POROS) study: design and baseline characteristics. Contemp Clin Trials 31(4):336–344CrossRefPubMed Schneider DL, Worley K, Beard MK, Iannini M, Ko M, McCallum J et al (2010) The primary care osteoporosis risk of fracture screening (POROS) study: design and baseline characteristics. Contemp Clin Trials 31(4):336–344CrossRefPubMed
36.
Zurück zum Zitat Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD (1995) The national patient registry. Evaluation of data quality. UgeskrLaeger 157(26):3741–3745 Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD (1995) The national patient registry. Evaluation of data quality. UgeskrLaeger 157(26):3741–3745
37.
Zurück zum Zitat Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 39(7 Suppl):12–16CrossRefPubMed Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 39(7 Suppl):12–16CrossRefPubMed
Metadaten
Titel
Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study
verfasst von
K. H. Rubin
M. J. Rothmann
T. Holmberg
M. Høiberg
S. Möller
R. Barkmann
C. C. Glüer
A. P. Hermann
M. Bech
J. Gram
K. Brixen
Publikationsdatum
07.12.2017
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 3/2018
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4326-3

Weitere Artikel der Ausgabe 3/2018

Osteoporosis International 3/2018 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.